What Depression Does to Brain Chemistry

The most familiar story about depression involves serotonin: not enough of it, and mood suffers. That account is not wrong, but it is incomplete. Depression disrupts multiple neurotransmitter systems simultaneously, and the downstream consequences extend well beyond how a person feels on a given day.

Among the most significant changes is what happens to BDNF (brain-derived neurotrophic factor), a protein that supports the growth, survival, and maintenance of neurons (brain cells). In people with depression, BDNF levels are often markedly reduced. This matters because BDNF is essentially the brain’s maintenance crew: without adequate levels, neurons in mood-regulating regions begin to atrophy, synaptic connections weaken, and the brain’s capacity to adapt and recover is compromised. Research has shown that ketamine directly increases BDNF, which may explain part of its rapid antidepressant effect (National Institutes of Health).

The hippocampus, a brain region central to memory formation and emotional regulation, is particularly vulnerable to these changes. Studies show that prolonged depression can actually reduce hippocampal volume, contributing to the memory difficulties and cognitive fog that many patients describe alongside low mood (National Institutes of Health). For Silicon Valley professionals who rely on sharp thinking, this aspect of depression’s neurological footprint is often deeply disruptive.

The Glutamate Gap That SSRIs Don’t Fill

First-line antidepressants, SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors), work by increasing the availability of serotonin and norepinephrine at synapses. They help a significant portion of people with depression, and we respect their role in treatment (National Institutes of Health). But they operate on a specific subset of the brain’s chemistry, and for patients whose depression involves substantial glutamate system dysregulation, serotonin-targeted treatment may simply not be addressing the right problem.

Glutamate is the brain’s primary excitatory neurotransmitter, it drives the vast majority of signaling between neurons. When the glutamate system is dysregulated, as appears to be the case in many forms of treatment-resistant depression, the brain loses some of its capacity for neuroplasticity: the ability to form new connections, reorganize existing pathways, and recover from damage. This is the gap that has made a growing number of clinicians and patients look past the standard antidepressant toolkit.

At Soft Reboot Wellness, Dr. Sara Herman, a Harvard-trained anesthesiologist who has guided more than 10,000 patients through anesthesia and ketamine therapy, built our practice around this understanding. The patients who find their way to us have frequently tried multiple antidepressants, often for years, and still feel stuck. Their experience is not a failure of willpower; it reflects a biological reality about which neurotransmitter systems their depression is actually engaging.

How Neuroplasticity Becomes the Target

Neuroplasticity, the brain’s ability to reorganize itself by forming new neural connections, is not a static trait. It can be increased or decreased by environment, stress, illness, and treatment. Chronic depression is one of the more reliable ways to suppress it; effective treatment for depression is one of the more reliable ways to restore it.

Research shows that ketamine promotes neuroplasticity in ways that standard antidepressants do not, and does so rapidly, changes that SSRIs typically require weeks to approximate can appear within hours of a ketamine infusion (National Institutes of Health). This speed is clinically meaningful. For someone in the grip of severe depression, a week matters. For someone who has been waiting for months across multiple medication trials, the prospect of a different timeline is significant.

The mechanism behind this rapid effect runs through NMDA receptor blockade and the subsequent release of glutamate in a pattern that activates neuroplasticity pathways. In plain terms: ketamine briefly disrupts the brain’s usual signaling, and when that disruption resolves, the brain rebuilds connections in a healthier pattern. It is a reset, not a permanent fix achieved in a single session, but a meaningful opening that, with appropriate integration support, can be built upon.

What This Means for Treatment-Resistant Depression

For patients who have not responded to two or more antidepressant trials, the neuroscience strongly suggests the problem is not that they haven’t found the right serotonin medication. The problem may be that the serotonin system is not the primary driver of their depression at all.

Our IV ketamine infusions at Soft Reboot Wellness target the glutamate system directly, bypassing the serotonin pathway entirely and addressing the neuroplasticity deficit that standard medications leave untouched. A standard induction series involves four to six infusions over four to six weeks, with the protocol personalized to your response. We use the Osmind EHR platform for mood tracking throughout, so progress is documented rather than impressionistic. For patients who want to use the neuroplastic window opened by ketamine for deeper psychological work, our ketamine-assisted psychotherapy (KAP) program adds a preparation session and integration coaching.

We also work closely with patients’ existing treatment teams. If you have a psychiatrist or therapist, we coordinate with them, with your permission, because the neurobiological changes ketamine may produce are best consolidated through ongoing therapeutic work. Results vary by individual, and we encourage you to discuss whether ketamine therapy is appropriate for your specific history with your current healthcare provider.

Addressing the Fear of Starting Something New

One barrier we hear from patients often is not skepticism about the science. It is the exhaustion that comes from having tried things before and having them not work. After multiple medication trials, hope becomes a liability that feels too expensive to extend again.

We understand that. Dr. Herman and our team approach every new patient with the awareness that they are arriving with a history, not just a diagnosis. The initial intake process is designed to give us a thorough picture of what you have tried, for how long, and how you responded, so our recommendations are grounded in your actual trajectory, not a generic protocol. Treatment is not appropriate for everyone, and we will tell you honestly if we do not think we are the right fit.

The cost of ketamine therapy is a real consideration. IV ketamine for mental health is an off-label treatment, and insurance coverage is not standard. We recommend contacting our team at hello@softrebootwellness.com or 650-419-3330 to discuss the financial realities before your consultation, so there are no surprises on either side of the conversation.

Frequently Asked Questions

Can depression actually shrink your brain? Research suggests prolonged depression is associated with reduced volume in the hippocampus and other mood-regulating regions, likely due to the neurotoxic effects of chronic stress hormones and reduced BDNF levels (National Institutes of Health). These changes are not necessarily permanent, effective treatment, including approaches that promote neuroplasticity, may help restore some of this lost volume over time. Results vary by individual.

Why do antidepressants take so long to work if depression is a brain chemistry problem? SSRIs and SNRIs modulate neurotransmitter availability gradually, and the downstream structural changes that correspond with symptom improvement, including neuroplasticity shifts, take weeks to develop. The delay is a function of how those medications work at the synaptic level. Ketamine’s mechanism differs: it triggers a rapid glutamate release and neuroplasticity cascade that can produce antidepressant effects much faster, often within hours of infusion (National Institutes of Health).

Does everyone with depression have glutamate dysregulation? Not necessarily. Depression is not a single condition with a single mechanism. Glutamate dysregulation appears to be more prominent in treatment-resistant presentations, people who have not responded to serotonin-targeting medications. This is part of why we conduct a thorough review of your treatment history before recommending IV ketamine therapy.

How does cognitive fog from depression relate to brain changes? The memory and concentration difficulties many people experience with depression are tied to the same neurobiological changes that affect mood, particularly reduced hippocampal function and BDNF depletion. Effective treatment that addresses these underlying mechanisms may improve cognitive symptoms alongside mood, though results vary significantly between individuals.

Key Takeaways

• Depression produces measurable changes in brain chemistry and structure, including reduced BDNF, hippocampal atrophy, and glutamate system dysregulation. It is not simply a mood state.
• Standard antidepressants target the serotonin and norepinephrine systems; they may not adequately address glutamate dysregulation, which is common in treatment-resistant presentations.
• Neuroplasticity, the brain’s capacity to form new connections, is suppressed by chronic depression and can be rapidly restored by ketamine infusion.
• Our IV ketamine therapy at Soft Reboot Wellness in Menlo Park directly targets the glutamate-neuroplasticity pathway that many patients have not yet addressed.
• Results vary by individual; treatment candidacy is determined through a thorough medical and psychiatric review.

If your depression has not responded the way you hoped to standard treatment, the neuroscience suggests you are not broken, you may simply need treatment that works on a different system. We are glad to talk through whether that is something we can help with. Call us at 650-419-3330 or email hello@softrebootwellness.com to start the conversation.

References

1. Mayo Clinic. Symptoms and causes of major depressive disorder. https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007
2. National Institutes of Health. Ketamine promotes neuroplasticity, the brain’s ability to form new neural connections, which may explain its rapid and sustained antidepressant effects. https://pmc.ncbi.nlm.nih.gov/articles/PMC8190578/
3. National Institutes of Health. Ketamine has been shown to increase brain-derived neurotrophic factor (BDNF), a protein essential for neuron growth and long-term mood regulation. https://pubmed.ncbi.nlm.nih.gov/39684808/
4. National Institutes of Health. Research documents the efficacy and limitations of SSRIs as a first-line treatment for depression and anxiety. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395812/
5. National Institutes of Health. Research shows depression can impair memory and cognitive function, which may be improved with effective treatment. https://pmc.ncbi.nlm.nih.gov/articles/PMC5835184/

Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. Treatment for depression, including IV ketamine therapy, should only be pursued under the supervision of a licensed medical provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.

The Moment of Infusion

When ketamine enters the bloodstream via IV, the delivery method used at Soft Reboot Wellness, it reaches peak plasma concentration quickly and crosses the blood-brain barrier efficiently. Within minutes of infusion onset, the drug begins binding to NMDA receptors: N-methyl-D-aspartate receptors that sit on the surface of neurons and play a central role in regulating how those neurons communicate.

NMDA receptors are part of the glutamate system (the brain’s primary excitatory neurotransmitter network), responsible for the majority of signaling between neurons (National Institutes of Health). Under normal circumstances, NMDA receptors open in response to glutamate binding and allow ions to flow across the neuron membrane, initiating electrical signals. Ketamine enters the receptor channel and blocks this flow. The receptor is occupied but not activated.

This blockade sounds suppressive, and in one narrow sense it is. But the downstream consequence is counterintuitive: blocking NMDA receptors transiently causes a compensatory surge of glutamate release in surrounding circuits. That surplus glutamate then activates a different receptor type, AMPA receptors, which triggers a cascade of intracellular signaling that ultimately promotes synaptic plasticity, or the strengthening and reorganization of neural connections (National Institutes of Health).

The Neuroplasticity Cascade

The AMPA activation that follows NMDA blockade sets off a series of events inside the neuron. Among the most important is the production and release of BDNF (brain-derived neurotrophic factor), a protein that supports the growth, survival, and formation of new synaptic connections (National Institutes of Health). BDNF is often called the brain’s fertilizer, and the analogy holds: it is what allows neurons to grow new dendritic spines: the tiny projections through which neurons receive signals from neighboring cells.

In a brain affected by depression or PTSD, this infrastructure has often been degraded. Chronic stress hormones suppress BDNF, weaken synaptic connections, and reduce the density of dendritic spines in regions like the prefrontal cortex and hippocampus, areas central to mood regulation, decision-making, and emotional context. Ketamine’s BDNF-stimulating effect begins reversing this within hours of infusion, which is the most credible explanation for why antidepressant effects appear so quickly compared to medications that require weeks to achieve similar downstream results.

Research published in Nature also points to a secondary mechanism: ketamine appears to interact with the brain’s opioid system in ways that may contribute independently to its antidepressant action (Nature). This suggests ketamine is not a single-pathway drug, it works through at least two distinct systems simultaneously, which may explain both its breadth of effect across different conditions and the variation in how individual patients respond.

Why IV Delivery Matters

Ketamine can be administered in several ways, intravenously, intramuscularly, as an intranasal spray, or as oral lozenges. Each route produces a different pharmacokinetic profile: different rates of absorption, different peak concentrations, different durations of effect.

IV delivery, the method used at Soft Reboot Wellness, produces the most precise and controllable pharmacological profile. The dose enters the bloodstream directly, with no absorption variability from the gut or nasal mucosa. Peak plasma levels are reached quickly and predictably. The physician can adjust the infusion rate in real time based on the patient’s response. For patients whose treatment history involves partial or inconsistent responses to other medication forms, this precision matters.

Dr. Sara Herman, our Harvard-trained anesthesiologist with more than two decades of experience administering IV medications, personally provides and monitors all infusion sessions. The clinical environment at our Menlo Park clinic includes continuous vital sign monitoring and immediate access to intervention if needed. The dose used in mental health treatment is a fraction of what is administered for surgical anesthesia, sub-anesthetic dosing is well-tolerated and carries a well-established safety profile when administered by qualified clinicians in an appropriately equipped setting.

The Hours and Days After Infusion

The acute pharmacological effects of a ketamine infusion, the altered perception, the dissociative quality, resolve fully within one to two hours of infusion completion. What persists is the neuroplastic change the infusion has initiated. BDNF levels remain elevated. New synaptic connections are forming. The brain’s default circuitry, including the default mode network, which governs self-referential thinking and is often overactive in depression, is temporarily reorganized.

The 48 to 72 hours following infusion represent what many clinicians describe as an integration window: the period during which the brain is most receptive to the consolidation of new patterns. This is why the timing of integration work matters. At Soft Reboot Wellness, our KAP program is structured specifically around this window, the preparation session happens before infusion, and the integration coaching sessions are timed to the period when the brain is most able to use the new neural architecture the infusion has created.

Research confirms that a series of infusions produces cumulative neuroplastic benefit, repeated sessions extend and deepen the changes initiated by the first (National Institutes of Health). Our standard induction protocol involves four to six IV infusions over four to six weeks, with the specific protocol calibrated to your clinical response and informed by mood data tracked through the Osmind platform throughout your treatment.

What the Pharmacology Means for Candidacy

The same mechanism that makes ketamine effective for many patients also creates genuine contraindications for others. Because ketamine increases blood pressure transiently during infusion, patients with uncontrolled hypertension or certain cardiovascular conditions require additional clinical judgment before proceeding. Patients with a history of psychosis or certain personality disorders may not be appropriate candidates, as the dissociative properties of ketamine carry different risk profiles in those populations. Active substance use disorders also require careful evaluation.

This is why the consultation and review process at Soft Reboot Wellness is thorough, not perfunctory. We review your full medical and psychiatric history, your current medications, and your prior treatment responses before making any recommendation. Results vary by individual, and we encourage you to discuss all options with your existing healthcare provider before deciding whether IV ketamine therapy is appropriate for you.

IV ketamine for mental health is an off-label treatment, and insurance coverage is not standard. We recommend contacting our team at 650-419-3330 or hello@softrebootwellness.com before your consultation so that cost is a clear part of your decision-making rather than a surprise afterward.

Frequently Asked Questions

Why does IV ketamine work faster than oral or nasal forms? IV delivery bypasses the absorption variability that affects oral and intranasal routes. The medication enters the bloodstream directly, reaching predictable peak plasma concentrations quickly and allowing the administering physician to adjust the dose in real time. This precision produces a more reliable pharmacological effect, which is one reason IV remains the method with the strongest clinical evidence base for psychiatric indications.

What is the difference between the acute effects of ketamine and the lasting antidepressant effects? The acute effects, altered perception, dissociation, dreamlike quality, are a product of active NMDA receptor blockade during the infusion and resolve within one to two hours. The lasting antidepressant effects are a product of the downstream neuroplastic cascade: BDNF elevation, synaptic connection formation, and dendritic spine growth that continue developing in the hours and days after the infusion ends. The experience and the therapeutic mechanism are related but distinct.

Does ketamine lose effectiveness over time with repeated infusions? Some patients do find that the response to maintenance infusions shifts over time, either diminishing or requiring different spacing. This is not universal, and the clinical picture varies considerably between individuals. We monitor response throughout treatment using mood tracking data and adjust the protocol accordingly. Some patients require only occasional boosters; others benefit from a more regular maintenance schedule.

How does the opioid system interaction affect the risk of dependence? The opioid system interaction identified in recent research does not mean ketamine functions as an opioid or carries comparable dependence risk. The interaction appears to occur at different receptor subtypes and at a different scale than classical opioid medications. Ketamine does carry its own potential for misuse at high doses outside clinical settings, which is one reason administration in a supervised clinical environment with appropriate screening is medically required.

Key Takeaways

• IV ketamine blocks NMDA receptors, triggering a compensatory glutamate surge that activates AMPA receptors and initiates a neuroplasticity cascade, the core mechanism of its antidepressant effect.
• BDNF elevation following infusion supports new synaptic connection formation in brain regions degraded by chronic depression or trauma.
• Emerging research suggests ketamine also interacts with the opioid system as a secondary pathway, pointing to a multi-mechanism pharmacological profile.
• IV delivery produces the most precise and controllable pharmacokinetic profile; Dr. Herman personally monitors all infusion sessions at our Menlo Park clinic.
• The 48 to 72 hours following infusion are the prime integration window; our KAP program is timed around this period to maximize the value of the neuroplastic changes ketamine initiates.

Knowing what ketamine does in the body, not just that it works, but how and why, puts you in a better position to decide whether it belongs in your treatment plan. We are glad to walk through that conversation in depth. Call us at 650-419-3330 or email hello@softrebootwellness.com to start the conversation.

References

1. National Institutes of Health. The glutamate neurotransmitter system is the brain’s primary excitatory system and a key pathway through which ketamine produces its therapeutic effects. https://www.ncbi.nlm.nih.gov/books/NBK62187/
2. National Institutes of Health. Ketamine promotes neuroplasticity, the brain’s ability to form new neural connections, which may explain its rapid and sustained antidepressant effects. https://pmc.ncbi.nlm.nih.gov/articles/PMC8190578/
3. National Institutes of Health. Ketamine has been shown to increase brain-derived neurotrophic factor (BDNF), a protein essential for neuron growth and long-term mood regulation. https://pubmed.ncbi.nlm.nih.gov/39684808/
4. Nature. Research suggests ketamine may also produce antidepressant effects by interacting with the brain’s opioid system, pointing to multiple mechanisms of action. https://www.nature.com/articles/s41591-025-03800-w
5. National Institutes of Health. Multiple ketamine infusion sessions have been shown to produce cumulative antidepressant benefits and extend remission periods in patients with depression. https://pmc.ncbi.nlm.nih.gov/articles/PMC6236511/

Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine therapy should only be pursued under the supervision of a licensed medical provider familiar with your full medical and psychiatric history. Individual results vary. Off-label treatments like IV ketamine for mental health conditions carry risks that should be discussed thoroughly with a qualified provider before beginning. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.

The Glutamate System: The Story Standard Care Underemphasizes

When researchers began looking seriously at why antidepressants work for some people and not others, attention shifted toward a neurotransmitter most patients have never heard of: glutamate. Unlike serotonin, which modulates mood as one signal among many, glutamate is the brain’s primary excitatory neurotransmitter, responsible for the vast majority of signaling between neurons (National Institutes of Health). It is involved in learning, memory, synaptic plasticity, and the brain’s ability to reorganize itself in response to experience.

In a healthy brain, glutamate signaling operates within a careful balance. In a depressed brain, that balance is disrupted, and the consequences ripple outward. The NMDA receptor (N-methyl-D-aspartate receptor), which sits at the center of glutamate signaling and plays a central role in synaptic plasticity, begins to malfunction (National Institutes of Health). Synaptic plasticity is the technical term for the brain’s capacity to strengthen or weaken the connections between neurons depending on how they are being used, the mechanism underlying learning, adaptation, and recovery. When NMDA receptor function falters, the brain loses some of this adaptability, and mood regulation suffers in ways that serotonin-targeting medications do not directly address.

This is not a niche theory. It is increasingly the central explanation for why treatment-resistant depression exists at all, and it is the scientific basis for why ketamine, which works primarily through NMDA receptor blockade, has attracted such serious clinical interest over the past two decades. For a deeper look at the brain changes depression produces, see our post on what depression does to the brain.

What Memory Difficulties Are Telling You

Many people with depression report that their cognition changes alongside their mood. Words come more slowly. Concentration requires effort that used to be effortless. Past memories feel dulled or inaccessible. These are not separate symptoms from the depression. They are part of the same underlying neurobiology (National Institutes of Health).

The hippocampus, a brain structure critical to memory formation and retrieval, is particularly sensitive to the stress hormones elevated in chronic depression. Over time, high cortisol (the primary stress hormone) damages neurons in the hippocampus, contributing to the cognitive symptoms that many patients find as debilitating as the emotional ones. For professionals in Silicon Valley, where cognitive performance is closely tied to professional identity and career functioning, this aspect of depression often carries its own separate weight.

Understanding that these cognitive difficulties have a biological basis, that they are not a character issue or a sign of diminished capability, is something we address directly with patients at Soft Reboot Wellness. The brain changes that depression produces are real, measurable, and in many cases reversible with treatment that targets the right systems.

Why SSRIs Leave a Gap for Some Patients

SSRIs, selective serotonin reuptake inhibitors, work by blocking the reabsorption of serotonin into neurons, keeping more of it active in the space between cells. They are a genuine first-line treatment option and help many people significantly (National Institutes of Health). But they do not touch the glutamate system. They do not directly address NMDA receptor dysfunction. And they typically require six to eight weeks before any meaningful clinical effect is evident, a timeline that reflects the slow, indirect path through which serotonin changes eventually influence neuroplasticity. For a detailed comparison of how ketamine and SSRIs differ mechanically, see our post on ketamine versus SSRI treatment.

For a patient whose depression is primarily driven by glutamate dysregulation and reduced synaptic plasticity, this means that even a well-chosen, well-tolerated SSRI at the right dose may simply be pulling a lever that isn’t connected to the problem. This is not a failure of the medication. It is a mismatch between mechanism and condition.

When patients come to us having tried multiple antidepressants without adequate relief, the working hypothesis we start with is not that the next SSRI or SNRI will be the answer. It is that the serotonin system may not be the primary driver of their depression, and that a treatment targeting glutamate and neuroplasticity directly may be what’s been missing.

What the Depressed Brain Needs to Recover

Recovery from depression, real recovery, not just symptom suppression, requires the brain to rebuild the neural architecture that chronic depression has degraded. This means restoring BDNF (brain-derived neurotrophic factor) levels to support neuron health, repairing synaptic connections in mood-regulating circuits, and re-establishing the kind of glutamate system balance that allows the brain to adapt, learn, and regulate emotion effectively.

Treatment that promotes this kind of recovery works differently than treatment that simply modulates neurotransmitter availability. Ketamine, administered as an IV infusion, blocks NMDA receptors transiently and triggers a downstream release of glutamate in a pattern that activates neuroplasticity pathways, essentially jumpstarting the repair process (National Institutes of Health). The effect is fast by psychiatric standards: many patients report meaningful mood changes within hours of their first infusion, with the neuroplastic effects persisting and consolidating in the days that follow.

At Soft Reboot Wellness, a standard ketamine induction series involves four to six IV ketamine infusions over four to six weeks. Dr. Sara Herman, a Harvard-trained anesthesiologist with Advanced Certificate training in psychedelic-assisted therapy, personally provides and monitors all infusion sessions. We track mood progress through the Osmind platform so you and our team can assess your response objectively rather than relying on memory alone. For patients who want to build on the neuroplastic window the infusions open, our ketamine-assisted psychotherapy (KAP) program adds structured preparation and integration work with a certified psychedelic integration coach.

The Scheduling and Cost Questions

We know that for many patients considering ketamine therapy, the questions are not only neurological. They are practical. How disruptive is this to a work schedule? What does it cost, and will insurance cover any of it?

On scheduling: a ketamine infusion session does not require days of recovery. Most patients return to regular activities the following day, and we offer appointment times designed to accommodate demanding professional schedules. To get started, call or email us directly, we send you an intake packet, Dr. Herman reviews it, and then determines whether to schedule a consultation.

On cost: IV ketamine for mental health is considered an off-label treatment, and insurance coverage is inconsistent. We recommend calling us at 650-419-3330 or contacting us at hello@softrebootwellness.com to discuss costs before your consultation so that financial clarity is part of the decision-making process, not an afterthought. Results vary by individual, and we encourage everyone to discuss their options with their healthcare provider before starting.

Frequently Asked Questions

If my depression involves glutamate, why didn’t my doctor tell me that? Glutamate’s role in depression has become much clearer in the research over the past two decades, but it hasn’t yet shifted mainstream prescribing practice in the same way serotonin science did. Most primary care providers and psychiatrists are appropriately focused on first-line serotonin-targeting medications, which help many patients. The glutamate conversation typically becomes relevant when those first-line options have not produced adequate results. We are happy to discuss where your history fits into this picture during a consultation.

Can the cognitive symptoms of depression, the brain fog and memory issues, improve with treatment? Research suggests they can, particularly when treatment addresses the underlying neurobiological disruption rather than just surface symptoms (National Institutes of Health). The hippocampal changes associated with chronic depression are not necessarily permanent, and treatments that promote neuroplasticity, including ketamine, may support cognitive recovery alongside mood improvement. Results vary significantly between individuals.

Is the glutamate system involved in anxiety as well? Yes. The glutamate and NMDA receptor systems are implicated in anxiety disorders as well as depression, which may help explain why patients with comorbid anxiety and depression sometimes see both improve with ketamine treatment. We treat anxiety at Soft Reboot Wellness and assess the full scope of a patient’s condition during the consultation process.

What makes Soft Reboot different from other ketamine clinics in the Bay Area? Our clinical foundation is built on Dr. Herman’s background as a Harvard-trained anesthesiologist with psychedelic medicine credentials and IFS therapy training, a combination that shapes both the safety standards and the integration approach of our practice. We also work actively with patients’ existing care teams, use structured mood tracking, and offer KAP for patients who want the infusion experience embedded in a broader therapeutic framework. We think the neuroplastic window ketamine opens is best used, not just survived.

Key Takeaways

• The depressed brain shows measurable disruptions in glutamate signaling, NMDA receptor function, and neuroplasticity, changes that serotonin-targeting medications do not directly address.
• Cognitive symptoms like brain fog and memory difficulties are part of the same underlying neurobiology as mood symptoms, not separate complaints.
• SSRIs work well for many patients, but do not directly treat glutamate dysregulation, leaving a gap that IV ketamine therapy is specifically designed to fill.
• IV ketamine at Soft Reboot Wellness in Menlo Park targets the NMDA receptor system, promoting rapid neuroplasticity and BDNF restoration.
• Results vary by individual; treatment is initiated following a thorough medical and psychiatric consultation.

Depression’s grip on the brain is real, but so is the brain’s capacity to change when it gets the right input. If you have been trying to feel better using tools that may not be reaching the right systems, we would like to talk with you about what else may be possible. Reach us at 650-419-3330 or email hello@softrebootwellness.com to start the conversation.

References

1. National Institutes of Health. The glutamate neurotransmitter system is the brain’s primary excitatory system and a key pathway through which ketamine produces its therapeutic effects. https://www.ncbi.nlm.nih.gov/books/NBK62187/
2. National Institutes of Health. NMDA receptors play a central role in synaptic plasticity and are the primary target of ketamine’s antidepressant action. https://pmc.ncbi.nlm.nih.gov/articles/PMC9965111/
3. National Institutes of Health. Research shows depression can impair memory and cognitive function, which may be improved with effective treatment. https://pmc.ncbi.nlm.nih.gov/articles/PMC5835184/
4. National Institutes of Health. Research documents the efficacy and limitations of SSRIs as a first-line treatment for depression and anxiety. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395812/
5. National Institutes of Health. Ketamine promotes neuroplasticity, the brain’s ability to form new neural connections, which may explain its rapid and sustained antidepressant effects. https://pmc.ncbi.nlm.nih.gov/articles/PMC8190578/

Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. Treatment for depression and related conditions, including IV ketamine therapy, should only be pursued under the supervision of a licensed medical provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.

What Ketamine Does in the Brain

Ketamine’s primary action is on NMDA receptors (N-methyl-D-aspartate receptors), which are part of the glutamate system (the brain’s main excitatory neurotransmitter network). By temporarily blocking these receptors, ketamine triggers a cascade of downstream effects that standard antidepressants (which work through serotonin and norepinephrine) do not produce (National Institutes of Health).

The most clinically important of these downstream effects is a rapid increase in synaptic plasticity: the brain’s ability to strengthen and reorganize connections between neurons. In depression, anxiety, and PTSD, neural circuits involved in mood regulation, fear processing, and self-referential thinking tend to become rigid and entrenched. Ketamine disrupts that rigidity. Research shows it promotes neuroplasticity in ways that standard antidepressants approximate only after weeks of daily dosing, and ketamine can produce this effect within hours of a single infusion (National Institutes of Health).

Ketamine also increases BDNF (brain-derived neurotrophic factor), a protein that supports neuron survival, growth, and the formation of new synaptic connections (National Institutes of Health). BDNF is often depleted in people with depression, and restoring it is thought to be one of the mechanisms through which antidepressant effects are sustained beyond the immediate post-infusion period. Additionally, emerging research published in Nature suggests ketamine may interact with the brain’s opioid system as a secondary mechanism, pointing to a treatment with more than one pathway of therapeutic action (Nature).

What Ketamine Therapy Does Clinically

The clinical picture that emerges from research is striking. Ketamine produces rapid and significant antidepressant effects, often within hours, in patients who have not responded to multiple prior treatments (National Institutes of Health). For patients with treatment-resistant depression, anxiety, or PTSD, this speed is not a minor detail. It represents a fundamentally different experience of treatment: rather than waiting six to eight weeks to know whether a medication is working, patients often know within days.

The effects of a single infusion are real but typically time-limited, most patients experience meaningful symptom relief for days to weeks following the first session. This is why a series of infusions is the standard approach rather than a single treatment. Research shows that both single and repeated ketamine infusions can treat depression and related conditions, with repeated infusions extending the duration and depth of benefit (American Journal of Psychiatry). Our standard induction protocol at Soft Reboot Wellness involves four to six IV infusions over four to six weeks, personalized to your clinical response.

Ketamine-assisted psychotherapy (KAP) pairs infusions with structured preparation and integration work, and research supports the combination producing more durable outcomes than ketamine alone (National Institutes of Health). Our KAP program includes a preparation session, two 2-hour in-office infusion sessions, and integration coaching with a certified psychedelic integration coach.

What the Experience Is Like

Patients considering ketamine therapy understandably want to know what they are signing up for on a sensory level. The honest answer is that experiences vary, but certain qualities are consistent.

During an IV ketamine infusion, patients typically notice the onset of effects within minutes. The experience often includes a sense of mental quieting, a loosening of the grip of ordinary anxious or depressive thought patterns. Some patients describe mild perceptual shifts: altered time perception, a floating or dreamlike quality, or vivid inner imagery. Some experience emotional content that feels meaningful or revealing. Others find it largely calm and neutral.

What the experience is not: frightening in the way many patients expect. The dissociative quality that makes some people hesitant tends, in practice, to feel more like relief than threat for most patients in a supervised clinical setting. Dr. Sara Herman personally monitors all infusion sessions at our Menlo Park clinic. Vital signs are tracked continuously. The altered state resolves fully before patients leave, typically within an hour of the infusion ending, and patients are required to have a ride home.

The 48 to 72 hours following a session are considered particularly significant for integration: the neuroplastic window opened by the infusion is still active, and this is an optimal time for reflection, journaling, and the kind of internal work our integration coaching is designed to support.

What Ketamine Therapy Does Not Do

Being clear about limitations is as important as explaining the evidence. Ketamine therapy is not a cure, and we do not present it as one. Results vary by individual, and some patients do not respond to ketamine in the way they hope. Some patients require ongoing maintenance infusions, single booster sessions typically scheduled three weeks to three months after the initial series, to sustain the benefits they achieve during induction.

Ketamine’s mental health applications are also off-label. The medication has been FDA-approved as an anesthetic since 1970, and its safety profile at therapeutic doses is well-established. But its use for depression, anxiety, and PTSD has not received formal FDA approval for those specific psychiatric indications, which means insurance coverage is inconsistent. We are transparent about this from the start of the process, contact our team at 650-419-3330 or hello@softrebootwellness.com before your consultation to discuss the financial realities clearly.

Ketamine is also not appropriate for everyone. Patients with certain psychiatric histories, active substance use disorders, or specific medical conditions may not be suitable candidates. Every patient undergoes a thorough medical and psychiatric review before any treatment is recommended, and we will tell you honestly if we think a different approach is better suited to your situation.

How Soft Reboot’s Approach Shapes the Outcome

The same medication administered in different contexts produces different results. This is not a marketing claim. It is a documented feature of how ketamine works. Research on KAP shows that the integration of psychotherapy with infusion treatment improves outcomes relative to infusion alone, which is why our clinical model is built around that integration rather than treating it as optional (National Institutes of Health).

Dr. Herman’s credentials reflect this philosophy directly. She holds an Advanced Certificate in Psilocybin-Assisted Therapy from the Integrative Psychiatry Institute, has completed training in Internal Family Systems (IFS) combined with ketamine-assisted psychotherapy, and has personally guided more than 10,000 patients through anesthesia, pain management, and ketamine therapy over her career. Dr. Natasha, our board-certified anesthesiologist who trained at UCSF, brings additional clinical depth to the monitoring and safety dimension of every session.

We also use the Osmind EHR and mood-tracking platform to document your progress throughout treatment. This means your response is tracked objectively, not reconstructed from memory at occasional check-ins, and can be reviewed alongside your existing treatment team if you have one. We actively coordinate with outside providers, with your consent, because we believe integrative care produces better outcomes than any single clinic working in isolation. You can learn more on our frequently asked questions page.

Frequently Asked Questions

How long does the antidepressant effect of ketamine last after an infusion series? For most patients completing a standard induction series, the reduction in depressive symptoms lasts approximately five weeks on average, with a range of roughly three weeks to two months. Individual responses vary considerably. Maintenance infusions, single booster sessions, can be used to sustain the benefit when symptoms begin to return, and some patients find they need these infrequently while others use them more regularly.

Does ketamine therapy work better for some conditions than others? The strongest evidence base exists for treatment-resistant depression and PTSD, both of which are conditions we treat at Soft Reboot Wellness. There is also meaningful clinical evidence for ketamine’s effectiveness in anxiety. We assess the fit between your diagnosis and the available evidence during your consultation, so our recommendation is grounded in what the research actually supports for your specific presentation.

Will I remember my infusion sessions? Most patients retain some memory of the experience, though the altered quality of consciousness during infusion means those memories may be impressionistic rather than sequential. Patients are encouraged to journal or reflect in the hours and days following their session, while the experience is still accessible. Our integration coaching component is specifically designed to help you make sense of and work with whatever arises.

Can ketamine therapy be used alongside talk therapy or other psychiatric treatment? Yes, and we actively encourage it. Ketamine therapy works well as a complement to ongoing psychotherapy, many patients find their therapy deepens during and after a ketamine series, precisely because the neuroplastic window makes habitual thought patterns more available for examination. We coordinate with outside therapists and psychiatrists with your consent throughout your treatment.

Key Takeaways

• Ketamine works through NMDA receptor blockade in the glutamate system, triggering rapid neuroplasticity and BDNF increases that standard antidepressants do not produce on the same timeline.
• Clinical research documents significant antidepressant and anti-PTSD effects that often appear within hours, a fundamentally different experience from the weeks-long timeline of standard medications.
• The experience during infusion is time-limited, monitored, and for most patients more calming than distressing.
• Ketamine is an off-label treatment for mental health conditions; insurance coverage is inconsistent, and candidacy is determined individually through a medical and psychiatric review.
• Results vary by individual; combining ketamine with integration support, as in our KAP program, is associated with more durable outcomes.

Understanding what ketamine therapy does is the first step toward knowing whether it might be right for you. We are glad to continue that conversation in person. Call us at 650-419-3330 or email hello@softrebootwellness.com to schedule a consultation at our Menlo Park clinic.

References

1. National Institutes of Health. Ketamine works by blocking NMDA receptors in the glutamate system, producing rapid antidepressant effects through a mechanism distinct from traditional antidepressants. https://pmc.ncbi.nlm.nih.gov/articles/PMC5148235/
2. National Institutes of Health. NMDA receptors play a central role in synaptic plasticity and are the primary target of ketamine’s antidepressant action. https://pmc.ncbi.nlm.nih.gov/articles/PMC9965111/
3. National Institutes of Health. Ketamine has been shown to increase brain-derived neurotrophic factor (BDNF), a protein essential for neuron growth and long-term mood regulation. https://pubmed.ncbi.nlm.nih.gov/39684808/
4. Nature. Research suggests ketamine may also produce antidepressant effects by interacting with the brain’s opioid system, pointing to multiple mechanisms of action. https://www.nature.com/articles/s41591-025-03800-w
5. National Institutes of Health. Ketamine has demonstrated rapid and significant antidepressant effects in clinical studies, often working within hours when traditional medications take weeks. https://www.nimh.nih.gov/news/science-updates/2024/new-hope-for-rapid-acting-depression-treatment
6. American Journal of Psychiatry. Research shows that both single and repeated ketamine infusions can treat treatment-resistant depression, with maintenance infusions extending the duration of benefit. https://psychiatryonline.org/doi/10.1176/appi.ajp.2018.18070834
7. National Institutes of Health. Research supports the integration of psychotherapy with ketamine treatment, showing that the combination may produce more durable and meaningful outcomes than ketamine alone. https://pmc.ncbi.nlm.nih.gov/articles/PMC9207256/

Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine therapy should only be pursued under the supervision of a licensed medical provider familiar with your full medical and psychiatric history. Individual results vary. Off-label treatments like IV ketamine for mental health conditions carry risks that should be discussed thoroughly with a qualified provider before beginning. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.